<DOC>
	<DOCNO>NCT02508532</DOCNO>
	<brief_summary>This Phase 1 , open-label , first-in-human ( FIH ) study design evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) antineoplastic activity BLU-285 , administer orally ( PO ) , adult patient unresectable GIST relapse refractory solid tumor . The study consist 2 part , dose-escalation part ( Part 1 ) expansion part ( Part 2 ) .</brief_summary>
	<brief_title>Phase 1 Study BLU-285 Patients With Gastrointestinal Stromal Tumors ( GIST ) Other Relapsed Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>For Part 1 : Histologically cytologicallyconfirmed diagnosis unresectable GIST another advance solid tumor . Patients unresectable GIST must disease progress follow imatinib least 1 follow : sunitinib , regorafenib , sorafenib , dasatinib , pazopanib experimental agent target KIT , disease D842 mutation PDGFRα gene . Patients advance solid tumor GIST must relapse refractory disease without available effective therapy . OR For Part 2 : Group 1 : Patients must confirm diagnosis unresectable GIST progress follow imatinib least 1 follow : sunitinib , regorafenib , sorafenib , dasatinib , pazopanib , experimental agent target KIT , patient D842V mutation PDGFRα . Group 2 : Patients must confirm diagnosis unresectable GIST D842V mutation PDGFRα gene . The PDGFRα mutation identify local central assessment , either archival tissue sample new tumor biopsy obtain prior treatment BLU285 . Groups 1 2 : A tumor sample ( archival tissue new tumor biopsy ) submit mutational testing . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 QT interval correct use Fridericia 's formula ( QTcF ) &gt; 450 millisecond Platelet count &lt; 90,000/mL Absolute neutrophil count &lt; 1000/mL Hemoglobin &lt; 9 g/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 x upper limit normal ( ULN ) hepatic metastasis present ; &gt; 5 × ULN hepatic metastasis present Total bilirubin &gt; 1.5 × ULN ; &gt; 3 × ULN direct bilirubin , &gt; 1.5 × ULN presence Gilbert 's Disease Estimated ( CockroftGault formula ) measure creatinine clearance &lt; 40 mL/min Brain malignancy metastasis brain History seizure disorder requirement antiseizure medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>